Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Maintenance of Remission After Discontinuation of Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05149495

Acronym

STOP-SST

Enrollment

100

Registered

2021-12-08

Start date

2021-10-01

Completion date

2023-03-20

Last updated

2021-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Keywords

Acromegaly, Pituitary microadenoma, Pituitary macroadenoma, Somatostatin analogues, Hormonal control

Brief summary

At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major subject (≥18 years old) * Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital * Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021 * In whom biological confirmation of recurrence has been demonstrated * Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes.

Exclusion criteria

* Subject having expressed opposition to participating in the study * Treatment pre and / or post surgery by radiotherapy * No recurrence * No treatment with a somatostatin analogue for recurrence * Subject under guardianship, curatorship or safeguard of justice

Design outcomes

Primary

Measure	Time frame
Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery.	Files analysed retrospectively from January 01, 2000 to September 01, 2021 will be examined]

Countries

France

Contacts

Primary ContactPhilippe BALTZINGER, MD

philippe.baltzinger@chru-strasbourg.fr33 3 88 12 75 82

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results